WO2020064995A1 - Utilisation de biomarqueurs représentant des voies cardiaques, vasculaires et inflammatoires permettant la prédiction d'une lésion rénale aiguë chez des patients atteints de diabète de type 2 - Google Patents

Utilisation de biomarqueurs représentant des voies cardiaques, vasculaires et inflammatoires permettant la prédiction d'une lésion rénale aiguë chez des patients atteints de diabète de type 2 Download PDF

Info

Publication number
WO2020064995A1
WO2020064995A1 PCT/EP2019/076155 EP2019076155W WO2020064995A1 WO 2020064995 A1 WO2020064995 A1 WO 2020064995A1 EP 2019076155 W EP2019076155 W EP 2019076155W WO 2020064995 A1 WO2020064995 A1 WO 2020064995A1
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
aki
risk
type
patients
Prior art date
Application number
PCT/EP2019/076155
Other languages
English (en)
Inventor
Pierre Jean SAULNIER
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Université de Poitiers
Centre Hospitalier Universitaire De Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Poitiers, Centre Hospitalier Universitaire De Poitiers filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of WO2020064995A1 publication Critical patent/WO2020064995A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Definitions

  • BIOMARKERS REPRESENTING CARDIAC, VASCULAR AND INFLAMMATORY PATHWAYS FOR THE PREDICTION OF ACUTE KIDNEY INJURY IN PATIENTS WITH TYPE 2 DIABETES
  • the present invention relates to use of biomarkers representing cardiac, vascular and inflammatory pathways for the prediction of acute kidney injury in patients with type 2 diabetes.
  • Acute kidney injury is a related to chronic kidney disease and death in patients from the general population, with or without type 2 diabetes. Nevertheless AKI biomarkers are rarely validated in diabetes population.
  • MR-proADM concentrations are associated with the doubling of serum creatinine and progression to ESRD [2], and with mortality [3] in type 2 diabetes patients.
  • Circulating sTNFR is associated in numerous epidemiological studies cross-sectionally with GFR and DKD [4-6] and prospectively with DKD progression and ESRD occurrence [7-12] in both type 1 diabetes and type 2 diabetes patients.
  • sTNFR2 has been associated with GFR variation in type 2 diabetes patients [13] as well as in type 1 diabetes patients. [14].
  • sTNFR2 and TNFR1 have also been associated with DKD structural lesions and especially with early glomerular lesions in type 2 diabetes [15] .
  • NT-proBNP has been reported to be associated with rapid kidney decline in elderly adults [16] and with ESRD in the general population [17].
  • a post-hoc analysis of a clinical trial also reported an association of NT-proBNP with ESRD in type 2 diabetes patients [18].
  • all 3 of these biomarkers were associated with rapid progression of eGFR in type 2 diabetes in a recent biomarker-panel study, and they were included in our study to further evaluate their combined value [19].
  • the panel of said 6 biomarkers representing cardiac, vascular and inflammatory pathways has never been investigated for the prediction of AKI over usual risk factors in patients with type 2 diabetes.
  • the present invention relates to use of biomarkers representing cardiac, vascular and inflammatory pathways for the prediction of acute kidney injury in patients with type 2 diabetes.
  • the present invention is defined by the claims.
  • the inventors aimed to explore the individual and combined prognostic value of 7 circulating candidate markers for AKI.
  • This include markers of cardiac and endothelial dysfunction (mid-regional-pro-adrenomedullin [MRproADM], angiopoietinlike-2 [ANGPTL2], N-terminal prohormone brain natriuretic peptide [NTproBNP]) oxidative stress (fluorescent advanced glycation endproducts [AGE], carbonyls), cardio-renal pathways (copeptin [CTproAVP]), and inflammation (soluble TNF receptor 1 [TNFR1]).
  • Cox models were used to estimate the risk of AKI for each biomarker at baseline after adjustement for usual risk factors: sex, diabetes duration, HbAlc, systolic blood pressure, GFR, ACR, use of antihypertensive, and history of cardiovascular disease. Hazard ratios were reported per 1 SD increment of the logarithm of the biomarker concentration.
  • meaniSD age was 64 ⁇ l l years, diabetes duration 14 ⁇ 10 years, HbAlc 7.8 ⁇ l.6 %, and eGFR 77 ⁇ 2l ml/min/l.73m 2 , and median (IQR) ACR 3 (1-10) mg/mmol.
  • IQR median
  • the present invention relates to a method of determining whether a patient suffering from type 2 diabetes is at risk of having acute kidney injury (AKI) comprising i) measuring the level of at least one biomarker representing cardiac, vascular or inflammatory pathways in a plasma sample obtained from the patient, ii) comparing the level measured at step i) with its corresponding predetermined reference value wherein detecting differential between the level measured at step i) and its corresponding predetermined reference value indicates whether the patient is or is not at risk of having acute kidney injury.
  • AKI acute kidney injury
  • Type 2 diabetes or“non-insulin dependent diabetes mellitus (NIDDM)” has its general meaning in the art. Type 2 diabetes often occurs when levels of insulin are normal or even elevated and appears to result from the inability of tissues to respond appropriately to insulin. Most of the type 2 diabetics are obese. As used herein the term “obesity” refers to a condition characterized by an excess of body fat. The operational definition of obesity is based on the Body Mass Index (BMI), which is calculated as body weight per height in meter squared (kg/m 2 ).
  • BMI Body Mass Index
  • Obesity refers to a condition whereby an otherwise healthy subject has a BMI greater than or equal to 30 kg/m 2 , or a condition whereby a subject with at least one co-morbidity has a BMI greater than or equal to 27 kg/m 2 .
  • An "obese subject” is an otherwise healthy subject with a BMI greater than or equal to 30 kg/m 2 or a subject with at least one co-morbidity with a BMI greater than or equal 27 kg/m 2 .
  • a "subject at risk of obesity” is an otherwise healthy subject with a BMI of 25 kg/m 2 to less than 30 kg/m 2 or a subject with at least one co-morbidity with a BMI of 25 kg/m 2 to less than 27 kg/m 2 .
  • the increased risks associated with obesity may occur at a lower BMI in people of Asian descent.
  • “obesity” refers to a condition whereby a subject with at least one obesity-induced or obesity-related co-morbidity that requires weight reduction or that would be improved by weight reduction, has a BMI greater than or equal to 25 kg/m 2 .
  • An “obese subject” in these countries refers to a subject with at least one obesity-induced or obesity- related co-morbidity that requires weight reduction or that would be improved by weight reduction, with a BMI greater than or equal to 25 kg/m 2 .
  • a "subject at risk of obesity” is a person with a BMI of greater than 23 kg/m 2 to less than 25 kg/m 2 .
  • the term "acute kidney injury” or "acute kidney failure” is typically identified by a rapid deterioration in renal function sufficient to result in the accumulation of nitrogenous wastes in the body (see, e.g., Anderson and Schrier (1994), in Harrison's Principles of Internal Medicine, l3th edition, Isselbacher et al, eds., McGraw Hill Text, New York). Rates of increase in BUN of at least 4 to 8 mmol/L/day (10 to 20 mg/dL/day), and rates of increase of serum creatinine of at least 40 to 80 mihoI/L/day (0.5 to 1.0 mg/dL/day), are typical in acute renal failure.
  • the term "Risk” in the context of the present invention relates to the probability (i.e. at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% of risk) that an event will occur over a specific time period (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 years), as in the conversion to AKI, and can mean a subject's "absolute” risk or "relative” risk.
  • Absolute risk can be measured with reference to either actual observation post measurement for the relevant time cohort, or with reference to index values developed from statistically valid historical cohorts that have been followed for the relevant time period.
  • Relative risk refers to the ratio of absolute risks of a subject compared either to the absolute risks of low risk cohorts or an average population risk, which can vary by how clinical risk factors are assessed. Odds ratios, the proportion of positive events to negative events for a given test result, are also commonly used (odds are according to the formula p/(l-p) where p is the probability of event and (1- p) is the probability of no event) to no- conversion.
  • Risk evaluation in the context of the present invention encompasses making a prediction of the probability, odds, or likelihood that an event or disease state may occur, the rate of occurrence of the event or conversion from one disease state to another, i.e., from a normal condition to loss of renal function or to one at risk of developing loss of renal function.
  • Risk evaluation can also comprise prediction of future clinical parameters, traditional laboratory risk factor values, or other indices of loss of renal function, either in absolute or relative terms in reference to a previously measured population.
  • the methods of the present invention may be used to make continuous or categorical measurements of the risk of conversion to loss of renal function, thus diagnosing and defining the risk spectrum of a category of subjects defined as being at risk of having loss of renal function.
  • the invention can be used to discriminate between normal and other subject cohorts at higher risk of having loss of renal function.
  • high risk refers to differences in the individual predisposition for developing a disease, disorder, complication or susceptibility therefor, preferably after a subject has been treated by one of the therapies referred to below, such as high-dose chemotherapy.
  • Said high, intermediate or low risk can be statistically analyzed.
  • the differences between a subject and a group of subjects having a high, intermediate or low risk are statistically significant.
  • the risk groups are analyzed as described in the accompanied Examples whereby explorative data analysis is carried out and the risk groups are formed with respect to the median, the 25% and the 75% percentiles. Differences in continuous variables of the groups are tested by Wilcoxon-Mann-Whitney Test or Kurskal-Wallis Test depending on the number of groups to be compared. For nominal or ordered categories, Fisher's exact or Chi2-Test for trend are applied. Without further ado, the person skilled in the art can carry out multivariant analysis with stratified versions of the aforementioned tests or Cox models in order to examine the independent impact of predictive factors and to establish the different risk groups.
  • the plasma sample may be obtained using methods well known in the art.
  • Plasma may then be obtained from the plasma sample following standard procedures of the field including, but not limited to, centrifuging the plasma sample, followed by pipetting of the plasma layer.
  • Platelet-free plasma (PFP) can be obtained following appropriate centrifugation.
  • the plasma sample obtained from the patient is a platelet free plasma sample.
  • the biomarkers are selected from markers of cardiac and endothelial dysfunction (mid-regional-pro-adrenomedullin [MRproADM], angiopoietinlike-2 [ANGPTL2], N-terminal prohormone brain natriuretic peptide [NTproBNP]) oxidative stress (fluorescent advanced glycation endproducts [AGE], carbonyls), cardio-renal pathways (copeptin [CTproAVP]), and inflammation (soluble TNF receptor 1 [TNFR1]).
  • markers of cardiac and endothelial dysfunction mid-regional-pro-adrenomedullin [MRproADM], angiopoietinlike-2 [ANGPTL2], N-terminal prohormone brain natriuretic peptide [NTproBNP]
  • oxidative stress fluorescent advanced glycation endproducts [AGE], carbonyls
  • CTproAVP cardio-renal pathways
  • inflammation soluble TNF receptor 1 [TNFR1]
  • the term“Mid-regional-pro-adrenomedullin” or“MR-proADM” has its general meaning in the art and refers to a fragmend of adrenomedullin of unknown function and with high ex vivo stability (Struck et al. (2004), Peptides 25(8): 1369-72). More particularly, mid-regional proANP comprises at least amino acid residues 53-90 of proadrenomedullin.
  • ANGPTF2 has its general meaning in the art and refers to the angiopoietin-related protein 2 also known as angiopoietin-like protein 2 is a protein that in humans is encoded by the ANGPTF2 gene.
  • NT-proBNP has its general meaning in the art and relates to a polypeptide comprising, preferably, 76 amino acids in length corresponding to the N-terminal portion of the human NT-proBNP molecule.
  • the structure of the human BNP and NT-proBNP has been described already in detail in the prior art, e.g., WO 02/089657, WO 02/083913, Bonow 1996, New Insights into the cardiac natriuretic peptides. Circulation 93: 1946-1950.
  • Human NT-proBNP as disclosed in EP 0 648 228 Bl or under GeneBank accession number NP-002512.1; GL4505433.
  • AGE refers to the compound which it modifies as the reaction product of either an advanced glycosylation endproduct or a compound which forms AGEs and the compound so modified, such as the bovine serum albumin (BSA).
  • BSA bovine serum albumin
  • AGEs include, but are not limited to, AGE-proteins (such as BSA-AGE), AGE-lipids, AGE-peptides, and AGE- DNA.
  • CTproAVP has its general meaning in the art and refers to a 39-amino acid-long peptide derived from the C-terminus of pre-pro-hormone of arginine vasopressin, neurophysin II and copeptin. The term is also known as copeptin.
  • TNFR1 has its general meaning in the art and is used herein to denote the human soluble tumour necrosis factor receptor type 1.
  • sTNFRl comprises the extracellular domain of the intact receptor and exhibits an approximate molecular weight of 30KDa.
  • the level of 1, 2, 3, 4, 5, or 6 biomarkers is determined in the plasma sample. In some embodiments, the level of MR-proADM, sTNFRl and NT-proBNP is determined in the plasma sample.
  • the measurement of the level of a biomarker (e.g. TNFR1) in the blood sample is typically carried out using standard protocols known in the art.
  • the method may comprise contacting the blood sample with a binding partner capable of selectively interacting with the biomarker (e.g. TNFR1) in the sample.
  • the binding partners are antibodies, such as, for example, monoclonal antibodies or even aptamers.
  • the binding may be detected through use of a competitive immunoassay, a non-competitive assay system using techniques such as western blots, a radioimmunoassay, an ELISA (enzyme linked immunosorbent assay), a“sandwich” immunoassay, an immunoprecipitation assay, a precipitin reaction, a gel diffusion precipitin reaction, an immunodiffusion assay, an agglutination assay, a complement fixation assay, an immunoradiometric assay, a fluorescent immunoassay, a protein A immunoassay, an immunoprecipitation assay, an immunohistochemical assay, a competition or sandwich ELISA, a radioimmunoassay, a Western blot assay, an immunohistological assay, an immunocytochemical assay, a dot blot assay, a fluorescence polarization assay, a scintillation proximity assay, a homogeneous time resolved fluorescence
  • the aforementioned assays generally involve the binding of the partner (ie. antibody or aptamer) to a solid support.
  • Solid supports which can be used in the practice of the invention include substrates such as nitrocellulose (e.g., in membrane or microtiter well form); polyvinylchloride (e.g., sheets or microtiter wells); polystyrene latex (e.g., beads or microtiter plates); polyvinylidine fluoride; diazotized paper; nylon membranes; activated beads, magnetically responsive beads, and the like.
  • An exemplary biochemical test for identifying specific proteins employs a standardized test format, such as ELISA test, although the information provided herein may apply to the development of other biochemical or diagnostic tests and is not limited to the development of an ELISA test (see, e.g., Molecular Immunology: A Textbook, edited by Atassi et al. Marcel Dekker Inc., New York and Basel 1984, for a description of ELISA tests). Therefore ELISA method can be used, wherein the wells of a microtiter plate are coated with a set of antibodies which recognize the biomarker (e.g. TNFR1). A sample containing or suspected of containing the biomarker (e.g. TNFR1) is then added to the coated wells.
  • a standardized test format such as ELISA test
  • the plate(s) can be washed to remove unbound moieties and a detectably labelled secondary binding molecule added.
  • the secondary binding molecule is allowed to react with any captured sample marker protein, the plate washed and the presence of the secondary binding molecule detected using methods well known in the art. Measuring the level of a biomarker (e.g.
  • TNFR1 may also include separation of the compounds: centrifugation based on the compound’s molecular weight; electrophoresis based on mass and charge; HPLC based on hydrophobicity; size exclusion chromatography based on size; and solid-phase affinity based on the compound's affinity for the particular solid-phase that is used.
  • said one or two biomarkers proteins may be identified based on the known "separation profile" e.g., retention time, for that compound and measured using standard techniques.
  • the separated compounds may be detected and measured by, for example, a mass spectrometer.
  • levels of immunoreactive biomarker e.g.
  • TNFR1 in a sample may be measured by an immunometric assay on the basis of a double-antibody "sandwich” technique, with a monoclonal antibody specific for a biomarker (e.g. TNFR1) (Cayman Chemical Company, Ann Arbor, Michigan).
  • said means for measuring a biomarker (e.g. TNFR1) level are for example i) the biomarker (e.g. TNFR1) buffer, ii) a monoclonal antibody that interacts specifically with the biomarker (e.g. TNFR1), iii) an enzyme-conjugated antibody specific for the biomarker (e.g. TNFR1) and a predetermined reference value of the biomarker (e.g. TNFR1).
  • the level of biomarkers are determined in the plasma sample by any method well known in the art and more preferably as described in the EXAMPLE.
  • a predetermined reference value can be relative to a number or value derived from population studies, including without limitation, such subjects having similar body mass index, total cholesterol levels, LDL/HDL levels, systolic or diastolic blood pressure, subjects of the same or similar age range, subjects in the same or similar ethnic group, and subjects having the same severity of type 2 diabetes.
  • Such predetermined reference values can be derived from statistical analyses and/or risk prediction data of populations obtained from mathematical algorithms and computed indices of metabolic syndrome.
  • the predetermined reference values are derived from the level of a biomarker in a control sample derived from one or more subjects who were not subjected to the event.
  • the predetermined reference value has to be determined in order to obtain the optimal sensitivity and specificity according to the function of the test and the benefit/risk balance (clinical consequences of false positive and false negative).
  • the optimal sensitivity and specificity can be determined using a Receiver Operating Characteristic (ROC) curve based on experimental data.
  • ROC Receiver Operating Characteristic
  • ROC curve is receiver operator characteristic curve, which is also known as receiver operation characteristic curve. It is mainly used for clinical biochemical diagnostic tests.
  • ROC curve is a comprehensive indicator that reflects the continuous variables of true positive rate (sensitivity) and false positive rate (1- specificity). It reveals the relationship between sensitivity and specificity with the image composition method.
  • a series of different cut-off values are set as continuous variables to calculate a series of sensitivity and specificity values. Then sensitivity is used as the vertical coordinate and specificity is used as the horizontal coordinate to draw a curve. The higher the area under the curve (AUC), the higher the accuracy of diagnosis.
  • the point closest to the far upper left of the coordinate diagram is a critical point having both high sensitivity and high specificity values.
  • the AUC value of the ROC curve is between 1.0 and 0.5. When AUC>0.5, the diagnostic result gets better and better as AUC approaches 1. When AUC is between 0.5 and 0.7, the accuracy is low. When AUC is between 0.7 and 0.9, the accuracy is moderate. When AUC is higher than 0.9, the accuracy is quite high. This algorithmic method is preferably done with a computer.
  • ROC curve such as: MedCalc 9.2.0.1 medical statistical software, SPSS 9.0, ROCPOWER.SAS, DESIGNROC.FOR, MULTIREADER POWER.SAS, CREATE-ROC.SAS, GB STAT VIO.O (Dynamic Microsystems, Inc. Silver Spring, Md., USA), etc.
  • the level of the biomarker is higher than its corresponding predetermined reference value, it is concluded that the patient is a risk of having AKI.
  • the level of the biomarker is lower than its corresponding predetermined reference value, it is concluded that the patient is a risk of having AKI.
  • Typical treatment position include weight management, physical activity, smoking cessation and medications.
  • Medicines for preventing typically includes Examples of drug suitable for the prevention of loss of renal function include but is not limited to inhibitors of the renin-angiotensin system (RAS), including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) or antidiabetic drugs such as insulin or Sodium-glucose co-transporter 2 (SGLT2) inhibitors among patients with diabetes.
  • RAS renin-angiotensin system
  • ACE angiotensin-converting enzyme
  • ARBs angiotensin II receptor blockers
  • antidiabetic drugs such as insulin or Sodium-glucose co-transporter 2 (SGLT2) inhibitors among patients with diabetes.
  • SGLT2 Sodium-glucose co-transporter 2
  • kits suitable for performing the method of the present invention which comprises means for measuring the biomarker of the present invention.
  • the kit comprises binding partner specific for the biomarker(s).
  • Said binding partners are antibodies as described above. In some embodiments, these antibodies are labelled as described above.
  • the kits described above will also comprise one or more other containers, containing for example, wash reagents, and/or other reagents capable of quantitatively detecting the presence of bound antibodies.
  • compartmentalised kit includes any kit in which reagents are contained in separate containers, and may include small glass containers, plastic containers or strips of plastic or paper.
  • kits may allow the efficient transfer of reagents from one compartment to another compartment whilst avoiding cross-contamination of the samples and reagents, and the addition of agents or solutions of each container from one compartment to another in a quantitative fashion.
  • kits may also include a container which will accept the tumor tissue sample, a container which contains the antibody(s) used in the assay, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, and like), and containers which contain the detection reagent.
  • the SURDIAGENE study is a French single-center inception cohort of type 2 diabetes patients regularly visiting the diabetes department at Poitiers University Hospital, France [20]. Patients were consecutively enrolled from 2002 to 2012 and outcome updates were performed every 2 years since 2007. Since this is a referral population, some participants may be more complicated than those in the general diabetes population. The Poitiers University Hospital Ethics Committee approved the design (CPP whatsoever III). All participants in the study gave their informed written consent.
  • a history of cardiovascular disease at baseline was defined as a personal history of myocardial infarction, and/or stroke.
  • Patients with a baseline eGFR ⁇ 30 ml/min/l.73m 2 and/or prior renal replacement therapy were excluded from the present analysis. Definition of outcomes
  • AKI defined according to The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines criteria [21]. Only serum creatinine criteria were used to diagnose and stage AKI, and, therefore, urinary output criteria were omitted. We considered the lowest creatinine value found between the dates of hospital admission and discharge as the reference creatinine value. We identified and classified AKI by comparing the highest creatinine value found during full hospitalization to the reference serum creatinine value. AKI was defined as an increase in serum creatinine by > 0.3mg/dL (>26.5 pmol/L) or > 1.5 baseline versus the reference serum creatinine level.
  • stage 1 1.5-1.9%, stage 2 2.0-2.9%, stage 3 >300%).
  • Stage 3 AKI was also defined by a serum creatinine increase of >4.0 mg/dL (>353.6 mmol/L). For each patient, we considered only the first episode of AKI.
  • Biomarker selection was based on existing evidence from the literature (manual literature review) and the availability of reliable validated assays to measure biomarker concentrations in small volumes of serum.
  • Serum and urine creatinine and urinary albumin were measured by colorimetry and immunoturbidimetry tests, respectively, on a COBAS System analyzer (Roche Diagnostics GmbH, Mannheim, Germany).
  • Glomerular filtration rate was estimated using the Chronic Kidney Disease Epidemiology (2009 CKD-EPI) creatinine equation.
  • Glycated hemoglobin was determined using a high-performance liquid chromatography method with a HA- 8160 analyzer (Menarini, Flrence, Italy).
  • Remaining samples were processed under standardized conditions and stored at -80°C in the Poitiers Biological Resource Center (BRC BB-0033-00068) undergoing only one prior freeze-thaw cycle prior to assay.
  • the fluorescence intensity of AGEs and the levels of carbonyls, ANGPTL2, CTproAVP, MR-proADM and NT-proBNP were measured in stored plasma-EDTA samples while sTNFRl was measured in stored serum.
  • Clinical covariates included in the models for biomarker selection were selected based upon their inclusion in known associations AKI or CKD: age, sex, diabetes duration, HbAi c, systolic blood pressure (SBP), use of antihypertensive, history of cardiovascular disease, eGFR, uACR...
  • AKI or CKD age, sex, diabetes duration, HbAi c, systolic blood pressure (SBP), use of antihypertensive, history of cardiovascular disease, eGFR, uACR...
  • Quantitative variables were expressed as means ⁇ standard deviation (SD) or medians (25 lh -75 lh percentile) for skewed distributions; qualitative variables were presented as frequencies and percentages. Because of non-Gaussian distribution, concentrations of biomarkers were log-transformed. Spearman’s correlations were used to assess the relationship of biomarkers with each other and with clinical variables. A complete case method was used to handle missing data. Thus, 2 subjects with at least one missing value for biomarkers were omitted in the present study. Patients with follow up less than 1 month were omitted, living 1342 participants included in the complete case study.
  • SD standard deviation
  • medians 25 lh -75 lh percentile
  • the hazard ratio (HR) of AKI for each biomarker measured at baseline was determined by using Cox proportional hazards regression. We tested each model for log-linearity and proportionality assumptions using Schoenfeld residuals. Results were given with HR and 95% confidence intervals and expressed for a l-SD increase in the distribution of the logarithm of the biomarker concentration.
  • model 1 models adjusted for age, sex, diabetes duration, HbAi c, systolic blood pressure (SBP), use of antihypertensive, history of cardiovascular disease, eGFR and uACR (model 2) as they represent established key markers associated with renal outcomes [26].
  • Interactions between sex and biomarkers for the association between biomarkers and AKI were evaluated by the addition of interaction terms into the corresponding regression model.
  • the Akaike's information criterion (AIC) was used to compare global fit among models (nested or not nested), the model with the smallest AIC was considered as the best model. Comparisons of model adequacy were assessed using the likelihood ratio Chi2 tests.
  • AKI-BRS weighted AKI biomarker risk score
  • X k log of biomarker concentration and p k are beta coefficients were derived from the model 2 Cox regression model and correspond to the log (HR) of the biomarker.
  • the study population included 1,343 patients with available samples and follow-up data. The clinical and biological characteristics of the patients are presented in Table 1.
  • each BRS remained independently associated with an increased risk of AKI ; both P ⁇ 0.000l.
  • n l,343 _
  • CT -pro A VP (pmol/L) 0.7 (0.6-0.9)
  • NT-pro BNP (pg/mL) 103 (47-262)
  • sTNFRl (pg/mL) 1816 (1544-2236)
  • Data are mean ⁇ standard deviation, median (25 th -75 th percentile) or n (%)
  • History of cardiovascular disease was defined as history of stroke and/or myocardial infarction prior to baseline
  • AU arbitrary unit
  • RAAS blocker Renin Angiotensin aldosterone system blocker (Angiotensin receptor blocker and/or ACE inhibitor); OAD agent, oral antidiabetic agent
  • eGFR estimated glomerular filtration rate by CKD EPI equation
  • uACR urinary albumin-to-creatinine ratio
  • MR- proADM Mid-regional-pro-adrenomedullin
  • Normalalbuminuria was defined as uACR ⁇ 30mg/g, microalbuminuria as uACR 30-299 mg/g and macroalbuminuria as uACR >300 mg/g
  • Ratios are presented for 1 SD increment with 95% confidence interval and P Value.
  • MR-proADM Mid-regional-pro-adrenomedullin
  • sTNFRl soluble Tumor Necrosis Factor receptor 1
  • NT-proBNP N-terminal prohormone brain natriuretic peptide Table 3-C-statistics, relative integrated discrimination improvement index (rIDI) using individual biomarkers or their combination for the prediction of renal function loss (> 40% GFR drop) and of rapid renal function decline ( ⁇ -5ml/min/year)
  • Reference Model age, sex, diabetes duration, systolic blood pressure, hbalc, eGFR, UACR
  • AIC Akaike information criterion
  • Relative IDI relative integrated discrimination improvement index
  • MR-proADM Mid-regional-pro-adrenomedullin
  • sTNFRl soluble Tumor Necrosis Factor receptor 1
  • NT-proBNP N-terminal prohormone brain natriuretic peptide
  • Kellum JA Lameire N
  • Group KAGW Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013; 17:204.

Abstract

L'invention porte sur la prédiction d'une lésion rénale aiguë (AKI) qui est une maladie liée à une maladie rénale chronique et à la mort chez des patients issus de la population générale, atteints ou non de diabète de type 2. Néanmoins, les biomarqueurs d'AKI sont rarement validés dans la population atteinte de diabète. Les inventeurs ont cherché à explorer une valeur pronostique individuelle et combinée de 7 marqueurs candidats circulants d'une AKI. Les marqueurs comprennent des marqueurs de dysfonctionnement cardiaque et endothélial (pro-adrénomédulline [MRproADM], angiopoïétine-2 [ANGPTL2], peptide natriurétique du cerveau de prohormone N-terminale [NTproBNP]), stress oxydatif (produits terminaux de glycation avancée fluorescents [AGE], carbonyles), voies cardio-rénales (copeptine [CTproAVP]), et inflammation (récepteur TNF soluble 1 [TNFR1]). Ils ont suivi de manière prospective 1345 participants (565 femmes/780 hommes) atteint de diabète de type 2 issus d'une cohorte d'un hôpital français à centre unique (SURDIAGENE). Dans une analyse univariée, chaque biomarqueur a été significativement associé à une AKI, et 6 sont restés associés après un réglage multivariable. L'ajout d'un score multimarqueur qui additionne des valeurs normalisées et pondérées desdits 6 marqueurs au modèle comprend des statistiques C significativement améliorées de facteurs de risque habituels (0,724 à 0,759, P<0,0001), et de performances prédictives de risque à 5 ans (indice d'amélioration de discrimination intégrée relative =0,435, P<0,0001). Ainsi, le panel de 6 biomarqueurs représentant des voies cardiaques, vasculaires et inflammatoires améliore la prédiction d'AKI sur des facteurs de risque usuels chez des patients atteints de diabète de type 2.
PCT/EP2019/076155 2018-09-28 2019-09-27 Utilisation de biomarqueurs représentant des voies cardiaques, vasculaires et inflammatoires permettant la prédiction d'une lésion rénale aiguë chez des patients atteints de diabète de type 2 WO2020064995A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306273.6 2018-09-28
EP18306273 2018-09-28

Publications (1)

Publication Number Publication Date
WO2020064995A1 true WO2020064995A1 (fr) 2020-04-02

Family

ID=63798917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/076155 WO2020064995A1 (fr) 2018-09-28 2019-09-27 Utilisation de biomarqueurs représentant des voies cardiaques, vasculaires et inflammatoires permettant la prédiction d'une lésion rénale aiguë chez des patients atteints de diabète de type 2

Country Status (1)

Country Link
WO (1) WO2020064995A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112259217A (zh) * 2020-09-16 2021-01-22 上海市第八人民医院 Sapsⅱ疾病危重性评分系统在年老的老年性急性肾损伤患者预后判断中的应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648228A1 (fr) 1992-06-03 1995-04-19 Medinnova Sf Anticorps du bnp et immuno-detection les utilisant
WO2002083913A1 (fr) 2001-04-13 2002-10-24 Biosite Diagnostics, Inc. Utilisation du peptide natriuretique de type b en tant qu'indicateur pronostique des syndromes coronariens aigus
WO2002089657A2 (fr) 2001-05-04 2002-11-14 Biosite, Inc. Marqueurs diagnostiques de syndromes coronaires aigus et leurs methodes d'utilisation
WO2009116023A1 (fr) * 2008-03-18 2009-09-24 Biotrin Intellectual Properties Limited, Procédé d'identification et de prédiction précoces d'une lésion rénale
WO2010025434A1 (fr) * 2008-08-29 2010-03-04 Astute Medical, Inc. Procédés et compositions pour le diagnostic et le pronostic de la blessure rénale et de l’insuffisance rénale
WO2010068686A2 (fr) * 2008-12-10 2010-06-17 Joslin Diabetes Center, Inc. Procédés de diagnostic et prédiction d'une maladie rénale
WO2012146645A1 (fr) * 2011-04-27 2012-11-01 Roche Diagnostics Gmbh Diagnostic de blessure du rein suite à une intervention chirurgicale
WO2014096110A1 (fr) * 2012-12-20 2014-06-26 Novartis Ag Insuffisance rénale aiguë
WO2014197729A1 (fr) * 2013-06-05 2014-12-11 Astute Medical, Inc. Procédés et compositions servant au diagnotic et au pronostic d'une atteinte rénale et d'une insuffisance rénale
WO2018069487A1 (fr) * 2016-10-14 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et kits de prédiction du risque de perte de fonction rénale chez des patients atteints de diabète de type 2

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0648228A1 (fr) 1992-06-03 1995-04-19 Medinnova Sf Anticorps du bnp et immuno-detection les utilisant
WO2002083913A1 (fr) 2001-04-13 2002-10-24 Biosite Diagnostics, Inc. Utilisation du peptide natriuretique de type b en tant qu'indicateur pronostique des syndromes coronariens aigus
WO2002089657A2 (fr) 2001-05-04 2002-11-14 Biosite, Inc. Marqueurs diagnostiques de syndromes coronaires aigus et leurs methodes d'utilisation
WO2009116023A1 (fr) * 2008-03-18 2009-09-24 Biotrin Intellectual Properties Limited, Procédé d'identification et de prédiction précoces d'une lésion rénale
WO2010025434A1 (fr) * 2008-08-29 2010-03-04 Astute Medical, Inc. Procédés et compositions pour le diagnostic et le pronostic de la blessure rénale et de l’insuffisance rénale
WO2010068686A2 (fr) * 2008-12-10 2010-06-17 Joslin Diabetes Center, Inc. Procédés de diagnostic et prédiction d'une maladie rénale
WO2012146645A1 (fr) * 2011-04-27 2012-11-01 Roche Diagnostics Gmbh Diagnostic de blessure du rein suite à une intervention chirurgicale
WO2014096110A1 (fr) * 2012-12-20 2014-06-26 Novartis Ag Insuffisance rénale aiguë
WO2014197729A1 (fr) * 2013-06-05 2014-12-11 Astute Medical, Inc. Procédés et compositions servant au diagnotic et au pronostic d'une atteinte rénale et d'une insuffisance rénale
WO2018069487A1 (fr) * 2016-10-14 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et kits de prédiction du risque de perte de fonction rénale chez des patients atteints de diabète de type 2

Non-Patent Citations (42)

* Cited by examiner, † Cited by third party
Title
"GeneBank", Database accession no. NP-002512.1
"Molecular Immunology: A Textbook", 1984, MARCEL DEKKER INC.
ANDERSONSCHRIER ET AL.: "Harrison's Principles of Internal Medicine", 1994, MCGRAW HILL TEXT
AXEL C. CARLSSON ET AL: "Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes", CARDIOVASCULAR DIABETOLOGY, vol. 15, no. 1, 29 February 2016 (2016-02-29), XP055342896, DOI: 10.1186/s12933-016-0359-8 *
BANSAL NKATZ RDALRYMPLE LDE BOER IDEFILIPPI CKESTENBAUM B ET AL.: "NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults", CLIN J AM SOC NEPHROL, vol. 10, 2015, pages 205 - 214, XP055342895, doi:10.2215/CJN.04910514
BONOW: "New Insights into the cardiac natriuretic peptides", CIRCULATION, vol. 93, 1996, pages 1946 - 1950
CARLSSON ACOSTGREN CJNYSTROM FHLANNE TJENNERSJO PLARSSON A ET AL.: "Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes", CARDIOVASC DIABETOL, vol. 15, 2016, pages 40, XP055342896, doi:10.1186/s12933-016-0359-8
COURNOT MBURILLO ESAULNIER PJPLANESSE CGAND EREHMAN M ET AL.: "Circulating Concentrations of Redox Biomarkers Do Not Improve the Prediction of Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus", J AM HEART ASSOC, 2018, pages 7
DESAI ASTOTO RJAROLIM PUNO HECKARDT KUKEWALRAMANI R ET AL.: "Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD", AM J KIDNEY DIS, vol. 58, 2011, pages 717 - 728, XP028320449, doi:10.1053/j.ajkd.2011.05.020
FINE JPGRAY RJ: "A proportional hazards model for the subdistribution of a competing risk", J AM STAT ASSOC, vol. 94, 1999, pages 496 - 509
FORSBLOM CMORAN JHARJUTSALO VLOUGHMAN TWADEN JTOLONEN N ET AL.: "Added value of soluble tumor necrosis factor-alpha receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes", DIABETES CARE, vol. 37, 2014, pages 2334 - 2342
GELLEN BARNABAS ET AL: "ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients", DIABETOLOGIA, SPRINGER, BERLIN, DE, vol. 59, no. 11, 4 August 2016 (2016-08-04), pages 2321 - 2330, XP036291240, ISSN: 0012-186X, [retrieved on 20160804], DOI: 10.1007/S00125-016-4066-5 *
GELLEN BTHORIN-TRESCASES NSOSNER PGAND ESAULNIER PJRAGOT S ET AL.: "ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients", DIABETOLOGIA, vol. 59, 2016, pages 2321 - 2330, XP036291240, doi:10.1007/s00125-016-4066-5
GILBERTO VELHO ET AL: "Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes", DIABETES, vol. 64, no. 9, 6 May 2015 (2015-05-06), US, pages 3262 - 3272, XP055342830, ISSN: 0012-1797, DOI: 10.2337/db14-1852 *
GOMEZ-BANOY NCUEVAS VHIGUITA AARANZALEZ LHMOCKUS I: "Soluble tumor necrosis factor receptor 1 is associated with diminished estimated glomerular filtration rate in colombian patients with type 2 diabetes", J DIABETES COMPLICATIONS, 2016
H. R. H. DE GEUS ET AL: "Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges", CLINICAL KIDNEY JOURNAL, vol. 5, no. 2, 26 March 2012 (2012-03-26), pages 102 - 108, XP055535699, ISSN: 2048-8505, DOI: 10.1093/ckj/sfs008 *
HADJADJ SFUMERON FROUSSEL RSAULNIER PJGALLOIS YANKOTCHE A ET AL.: "Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects", DIABETES CARE, vol. 31, 2008, pages 1847 - 1852
HORNUNG RWREED LD: "Estimation of Average Concentration in the Presence of Nondetectable Values", APPLIED OCCUPATIONAL AND ENVIRONMENTAL HYGIENE, vol. 5, 1990, pages 46 - 51
KARTHIKEYAN KANDASAMY ET AL: "Prediction of drug-induced nephrotoxicity and injury mechanisms with human induced pluripotent stem cell-derived cells and machine learning methods", SCIENTIFIC REPORTS, 27 July 2015 (2015-07-27), England, pages 12337, XP055535702, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080076/pdf/10.1177_2054358118776326.pdf> DOI: 10.1038/srep12337 *
KELLUM JALAMEIRE NGROUP KAGW: "Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1", CRIT CARE, vol. 17, 2013, pages 204
KIM YMATSUSHITA KSANG YGRAMS MESKALI HSHAH AM ET AL.: "Association of high-sensitivity cardiac troponin T and natriuretic peptide with incident ESRD: the Atherosclerosis Risk in Communities (ARIC) study", AM J KIDNEY DIS, vol. 65, 2015, pages 550 - 558, XP029205881, doi:10.1053/j.ajkd.2014.08.021
LANDMAN GWVAN DIJK PRDRION IVAN HATEREN KJSTRUCK JGROENIER KH ET AL.: "Midregional fragment of proadrenomedullin, new-onset albuminuria, and cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-30", DIABETES CARE, vol. 37, 2014, pages 839 - 845
LASSALLE MAYAV CFRIMAT LJACQUELINET CCOUCHOUD C: "R. The essential of 2012 results from the French Renal Epidemiology and Information Network (REIN) ESRD registry", NEPHROL THER, vol. 11, 2015, pages 78 - 87
LOOKER HCCOLOMBO MHESS SBROSNAN MJFARRAN BDALTON RN ET AL.: "Biomarkers of rapid chronic kidney disease progression in type 2 diabetes", KIDNEY INT, 2015
LOPES-VIRELLA MFBAKER NLHUNT KJCLEARY PAKLEIN RVIRELLA G: "Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects", DIABETES CARE, vol. 36, 2013, pages 2317 - 2323
M. E. HELLEMONS ET AL: "Validity of biomarkers predicting onset or progression of nephropathy in patients with Type?2 diabetes: a systematic review", DIABETIC MEDICINE., vol. 29, no. 5, 16 April 2012 (2012-04-16), GB, pages 567 - 577, XP055342826, ISSN: 0742-3071, DOI: 10.1111/j.1464-5491.2011.03437.x *
MIYAZAWA IARAKI SOBATA TYOSHIZAKI TMORINO KKADOTA A ET AL.: "Association between serum soluble TNFalpha receptors and renal dysfunction in type 2 diabetic patients without proteinuria", DIABETES RES CLIN PRACT, vol. 92, 2011, pages 174 - 180, XP055071823, doi:10.1016/j.diabres.2011.01.008
N. BANSAL ET AL: "NT-ProBNP and Troponin T and Risk of Rapid Kidney Function Decline and Incident CKD in Elderly Adults", CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 10, no. 2, 20 January 2015 (2015-01-20), pages 205 - 214, XP055342895, ISSN: 1555-9041, DOI: 10.2215/CJN.04910514 *
NG DPFUKUSHIMA MTAI BCKOH DLEONG HIMURA H ET AL.: "Reduced GFR and albuminuria in Chinese type 2 diabetes mellitus patients are both independently associated with activation of the TNF-alpha system", DIABETOLOGIA, vol. 51, 2008, pages 2318 - 2324, XP019651344, doi:10.1007/s00125-008-1162-1
NIEWCZAS MAFICOCIELLO LHJOHNSON ACWALKER WROSOLOWSKY ETROSHAN B ET AL.: "Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes", CLIN J AM SOC NEPHROL, vol. 4, 2009, pages 62 - 70, XP002683004, doi:10.2215/CJN.03010608
NIEWCZAS MAGOHDA TSKUPIEN JSMILES AMWALKER WHROSETTI F ET AL.: "Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes", J AM SOC NEPHROL, vol. 23, 2012, pages 507 - 515, XP055262558, doi:10.1681/ASN.2011060627
NINOMIYA TPERKOVIC VDE GALAN BEZOUNGAS SPILLAI AJARDINE M ET AL.: "Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes", J AM SOC NEPHROL, vol. 20, 2009, pages 1813 - 1821
PAVKOV MENELSON RGKNOWLER WCCHENG YKROLEWSKI ASNIEWCZAS MA: "Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes", KIDNEY INT, vol. 87, 2015, pages 812 - 819
PAVKOV MEWEIL EJFUFAA GDNELSON RGLEMLEY KVKNOWLER WC ET AL.: "Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes", KIDNEY INT, 2015
PENCINA MJD'AGOSTINO RB, SR.D'AGOSTINO RB, JR.VASAN RS: "Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond", STAT MED, vol. 27, 2008, pages 157 - 172, XP055399798, doi:10.1002/sim.2929
PENCINA MJD'AGOSTINO RB: "Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation", STATISTICS IN MEDICINE, vol. 23, 2004, pages 2109 - 2123
SAULNIER PJGAND ERAGOT SDUCROCQ GHALIMI JMHULIN-DELMOTTE C ET AL.: "Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort", DIABETES CARE, vol. 37, 2014, pages 1425 - 1431, XP055530205, doi:10.2337/dc13-2580
SAULNIER PJGAND EVELHO GMOHAMMEDI KZAOUI PFRATY M ET AL.: "Association of Circulating Biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) With Renal Function Decline in Patients With Type 2 Diabetes: A French Prospective Cohort", DIABETES CARE, vol. 40, 2017, pages 367 - 374
SIMONA POZZOLI ET AL: "Predicting acute kidney injury: current status and future challenges", JOURNAL OF NEPHROLOGY : JN, vol. 31, no. 2, 17 April 2018 (2018-04-17), IT, pages 209 - 223, XP055535728, ISSN: 1121-8428, DOI: 10.1007/s40620-017-0416-8 *
SKUPIEN JWARRAM JHNIEWCZAS MAGOHDA TMALECKI MMYCHALECKYJ JC ET AL.: "Synergism between circulating tumor necrosis factor receptor 2 and HbAlc in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria", DIABETES CARE, vol. 37, 2014, pages 2601 - 2608
STRUCK ET AL., PEPTIDES, vol. 25, no. 8, 2004, pages 1369 - 72
VELHO GRAGOT SMOHAMMEDI KGAND EFRATY MFUMERON F ET AL.: "Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes", DIABETES, vol. 64, 2015, pages 3262 - 3272, XP055342830, doi:10.2337/db14-1852

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112259217A (zh) * 2020-09-16 2021-01-22 上海市第八人民医院 Sapsⅱ疾病危重性评分系统在年老的老年性急性肾损伤患者预后判断中的应用

Similar Documents

Publication Publication Date Title
US20120219943A1 (en) Methods of prognosis and diagnosis in chronic heart failure
US9753039B2 (en) Prognosis of adverse events in patients with suspected chronic heart failure
JP6055005B2 (ja) 糖尿病の予測バイオマーカーとしてのアルギニンバソプレシンプロホルモン
EP2095107A2 (fr) Procédés et compositions permettant de surveiller et de prévoir les risques du syndrome cardio-rénal
EP1970709B1 (fr) Utilisation de peptides de type BNP pour la prédiction de besoins de dialyse
RU2765212C2 (ru) Гистоны и/или proadm в качестве маркеров, свидетельствующих о неблагоприятном событии
EP2646822B1 (fr) Procédés pour le diagnostic et la prédiction du risque d&#39;insuffisance cardiaque
WO2010143423A1 (fr) Méthode de détection d&#39;une néphropathie diabétique
EP2279419A1 (fr) Facteur gdf-15 utilisé comme biomarqueur dans le diabète de type 1
RU2733471C2 (ru) Способ прогнозирования риска развития хронического заболевания почек
WO2018069487A1 (fr) Procédés et kits de prédiction du risque de perte de fonction rénale chez des patients atteints de diabète de type 2
CA2605247A1 (fr) Dispositifs et methodes permettant de diagnostiquer ou de predire des dysfonctionnements cardiaques a un stade precoce
WO2011023813A1 (fr) Procalcitonine utilisée à des fins de pronostic d&#39;effets indésirables
WO2020064995A1 (fr) Utilisation de biomarqueurs représentant des voies cardiaques, vasculaires et inflammatoires permettant la prédiction d&#39;une lésion rénale aiguë chez des patients atteints de diabète de type 2
EP2153233A1 (fr) Méthode d évaluation de la gravité d un dysfonctionnement des organes en utilisant la chromogranine a comme marqueur.
Kawamura et al. Plasma and serum prorenin concentrations in diabetes, hypertension, and renal disease
US20180156822A1 (en) Biomarker for cardiac disorders
EP3004891B1 (fr) Biomarqueur de réhospitalisation après une insuffisance cardiaque
EP3186639B1 (fr) Neprilysin comme marqueur pronostique pour l&#39;insuffisance cardiaque
RU2775090C2 (ru) Проадреномедуллин в качестве маркера, указывающего на неблагоприятное событие
WO2019238554A1 (fr) Procédés de prédiction du risque d&#39;avoir une maladie artérielle des extrémités inférieures chez des patients souffrant de diabète de type 2
Matsha et al. and iron status in patients with oesophageal cancer and healthy control subjects from Transkei, South Africa
WO2009150249A1 (fr) Nt-probnp en tant qu’indicateur de pronostic du développement d’une insuffisance rénale terminale dans le diabète sucré

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19773448

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19773448

Country of ref document: EP

Kind code of ref document: A1